Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22275730 | 0.85 | ALDH1A1 (0.51) | SIGMAR1GAATAAR1 | |
| SCHEMBL22275736 | 0.83 | CYP1A2 (0.50) | SIGMAR1GAADAO | |
| SCHEMBL22263120 | 0.82 | DAO (0.42) | SIGMAR1HTR1ADAO | |
| SCHEMBL20932676 | 0.80 | ALDH1A1 (0.46) | SIGMAR1GAATAAR1 | |
| SCHEMBL20932774 | 0.79 | CYP1A2 (0.48) | SIGMAR1 | |
| SCHEMBL14286347 | 0.77 | GAA (0.47) | GAA | |
| SCHEMBL22262985 | 0.76 | GPR84 (0.38) | DAO | |
| SCHEMBL20932675 | 0.76 | SIGMAR1 (0.41) | SIGMAR1HRH3HTR1AGAAABCB1 | |
| SCHEMBL20932242 | 0.76 | SIGMAR1 (0.41) | SIGMAR1HRH3HTR1AGAAABCB1 | |
| SCHEMBL19019864 | 0.75 | GFER (0.53) | SIGMAR1HTR1ADAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092020-A1 | IDO/TDO Inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-03-20 | — | — | US | disclosed |
| US-12209079-B2 | IDO/TDO inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-01-28 | — | — | US | disclosed |
| US-20220380305-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. | 2022-12-01 | — | — | US | disclosed |
| US-20200239452-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| US-20200239452-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209079-B2 | IDO/TDO inhibitor | IDO1, IDO2, TDO2 | SIGMAR1 1856/4885HRH3 303/4885HTR1A 1094/4885 |
| US-20200239452-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | SIGMAR1 1856/4885HRH3 303/4885HTR1A 1094/4885 |
| US-20250092020-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | SIGMAR1 1856/4885HRH3 303/4885HTR1A 1094/4885 |
| US-20220380305-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | SIGMAR1 2269/4885HRH3 161/4885HTR1A 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.